15
November

08:00 AM EST

Medicinal Chemistry

Strategy Meeting East Coast USA 2022

Reinvigorating Productivity in Pharma & Biotech R&D Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Le Meridien Cambridge Boston

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our 2022 Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.

Dr. Tao Guo

SVP and Head WuXi AppTec

Andreas Schoops

Head of Medicinal Chemistry WuXi AppTec

Greg Makara

CEO ChemPass

Onur Atasoylu

Director, Head of Computational Chemistry Incyte

Matt Bursavich

Associate Vice President, Chemical Sciences Eli Lilly

Heather Carlson

Vice President Chemical Data Sciences Odyssey Therapeutics

Richard Heidebrecht

Vice President of Research and Development Glycologix

Jason Imbriglio

Vice President, Head of Discovery Chemistry Roivant Discovery

Jason brings more than 16 years of drug discovery and medicinal chemistry expertise to <a href="https://www.roivant.com/science">Roivant Discovery</a>.
Prior to joining Roivant, Jason was a recognized leader in Merck’s global discovery chemistry department where he held positions of increasing responsibility, most recently as director of chemical biology, leading teams across all levels of preclinical discovery including target identification, target validation, lead identification and lead optimization. Jason was a founding member of Merck’s chemical biology group and a co-lead of Merck’s targeted protein degradation group. Jason contributed to the discovery of five development candidates, three INDs and was a co-inventor in the discovery of the beta-lactamase inhibitor Relebactam.
Jason has authored over 30 peer-reviewed journal articles and holds 12 patents spanning a diverse set of therapeutic areas. He holds a bachelor of arts degree in biology and bachelor of science degree in chemistry from the University of Massachusetts in Amherst, Mass. where he was a recognized Howard Hughes Undergraduate Research Fellow, a doctor of philosophy degree in organic chemistry from the University of Arizona in Tucson, Az. and a National Institute of Health Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship at Boston College in Chestnut Hill, Mass.

Kevin Kreutter

Vice President, Drug Discovery Empress Therapeutics

Stephanos Loannidis

EVP Drug Discovery Exo Therapeutics

Kristen Marino

Senior Scientist II, Computational Chemistry Cellarity

Andrew McRiner

Vice President, Head of Drug Discovery Auron Therapeutics

Benoit Moreau

Head of Medicinal Chemistry Remix Therapeutics

Robb Nicewonger

Senior Director, Medicinal Chemistry Cellarity

Ed Olhava

Senior Vice President, Preclinical Development IFM Therapeutics

Over his nearly 20 year career in mid and early-stage biotech, Ed Olhava has invented and progressed multiple compounds through discovery and into clinical development. He has focused on discovering first-in-class small molecule modulators of new biological pathways, closely integrating medicinal chemistry, pharmacology, safety and CMC to enter clinical trials with these novel entities.
Before joining <a href="https://www.ifmthera.com/">IFM</a>, Ed was a strategic advisor at Third Rock Ventures, where he developed the strategic and operational plans for the drug discovery groups of two Third Rock seed companies, both of which were successfully funded and launched. Prior to Third Rock, he was a founding scientist at Epizyme, joining the company as the first medicinal chemist. He started the medicinal chemistry group and invented Epizyme’s first clinical compound and the first clinical histone methyltransferase inhibitor, EPZ-5676, leading activities from hit finding to filing the Investigational New Drug application. Before joining Epizyme, Ed began his medicinal chemistry career at Millennium Pharmaceuticals, where he co-invented NINLARO, approved in 2015 for the treatment of multiple myeloma, and MLN-4924.
Ed obtained his Ph.D. in synthetic organic chemistry from Harvard University and B.S. in chemistry from Stanford University. He is co-author/inventor on more than 40 papers and patents.

Lewis Pennington

Senior Director. Head of Platform Chemistry Kymera Therapeutics

Nisha Perez

Senior Director, Head of DMPK ROME Therapeutics

Jennifer Petter

Founder and Chief Scientific Officer Arrakis Therapeutics

Daniel J. Price

Executive Director, Head of Computational Chemistry Nimbus Therapeutics

Dr. Daniel Price is Executive Director and Head of Computational Chemistry at Nimbus Therapeutics. Before joining Nimbus, he a Senior Director in Computational Sciences at GlaxoSmithKline, where he led a small team of computational chemists, chemoinformaticians and data scientists operating across diverse areas of structure- and ligand-based drug design, high-content screening analytics, predictive ADME, predictive synthesis, and chemogenomics. He has led drug discovery programs, contributed to 4 clinical candidates, led the development of GSK’s first-generation R&D “data lake”, and authored/co-authored 25 publications. Dr. Price received his undergraduate degree in chemical engineering from University of Colorado at Boulder followed by his Ph.D. in Molecular Biophysics & Biochemistry from Yale University with Prof. Bill Jorgensen. He completed an NIH postdoctoral fellowship with Prof. Charlie Brooks, III at The Scripps Research Institute prior to joining GSK.

Aimee Usera

Senior Vice President Drug Discovery Odyssey Therapeutics

First name	Last name	Job title	Company name	Photo URL	Bio Position
Dr.	Tao Guo	SVP and Head	WuXi AppTec	https://proventainternational.com/wp-content/uploads/2022/10/Tao-Guo.jpg	Dr. Tao Guo is SVP and Head of WuXi Chemistry – Research Chemistry Services Business Development and Integrated Program Management, WuXi AppTec. He has over 30 years of experience in drug discovery. He was trained as an organic chemist with PhD from Columbia University and PostDoc from UC Berkeley. He is the recipient of 43 issued US patents and an inventor of 10 clinical candidate compounds with 1 approved by FDA.
Andreas	Schoops	Head of Medicinal Chemistry	WuXi AppTec	https://proventainternational.com/wp-content/uploads/2022/10/Andreas-Schoop.jpg
Greg	Makara	CEO	ChemPass	https://proventainternational.com/wp-content/uploads/2022/10/Greg-Makara.jpg
Onur	Atasoylu	Director, Head of Computational Chemistry	Incyte	https://proventainternational.com/wp-content/uploads/2022/08/Onur-Atasoylu-1.jpg	Onur Atasoylu obtained his Ph.D. from University of Pennsylvania in organic chemistry and undertook postdoctoral research at the University of Oxford, UK. He held various academic and industry positions in medicinal chemistry before joining Incyte Corporation in 2015. As the Head of Computational Chemistry at Incyte his research focuses on the design of small molecule inhibitors of targets in oncology and immunology.
Matt	Bursavich	Associate Vice President, Chemical Sciences	Eli Lilly	https://proventainternational.com/wp-content/uploads/2022/10/Matt-Bursavich-1.jpg
Heather	Carlson	Vice President Chemical Data Sciences	Odyssey Therapeutics	https://proventainternational.com/wp-content/uploads/2022/08/Heather-Carlson.jpg	Carlson received her Ph.D. with Prof. William L. Jorgensen at Yale. She studied protein simulations with Prof. J. Andrew McCammon at UCSD. Carlson began her academic career at the University of Michigan in 2000 as the John Gideon Searle Assistant Professor of Medicinal Chemistry. She was promoted in 2011 to Professor of Medicinal Chemistry (College of Pharmacy). She has published over 90 papers and received over $17M in grant funding. She was Chair of the Department of Medicinal Chemistry from 2021-2022. In January 2022, Carlson began her transition to biotech. She currently works for Odyssey Therapeutics in Ann Arbor, MI.
Richard	Heidebrecht	Vice President of Research and Development	Glycologix	https://proventainternational.com/wp-content/uploads/2021/02/Richard-Heidebrecht-scaled.jpg	Rich Heidebrecht is currently the Vice President of Research and Development at Glycologix. He started his career at Pfizer and Merck before making a transition to Biotech via the Broad Institute. Rich has gained expertise in medicinal, process and analytical chemistry and has worked on diverse therapeutic modalities such as small molecules, cell therapies, medical devices, and polymers including oligonucleotides. Over the course of his career, Rich has contributed to 35 patent/patent applications, 16 papers, two clinical programs and one marketed drug. Doctor Heidebrecht completed his undergraduate work at Worcester Polytechnic Institute and his graduate work at Indiana University with David R. Williams. His postdoc with Stephen Martin at the University of Texas at Austin rounded out two natural product synthesis projects – one total, one formal.
Jason	Imbriglio	Vice President, Head of Discovery Chemistry	Roivant Discovery	https://proventainternational.com/wp-content/uploads/2022/08/Jason-Imbriglio.jpg	Jason brings more than 16 years of drug discovery and medicinal chemistry expertise to Roivant Discovery. Prior to joining Roivant, Jason was a recognized leader in Merck’s global discovery chemistry department where he held positions of increasing responsibility, most recently as director of chemical biology, leading teams across all levels of preclinical discovery including target identification, target validation, lead identification and lead optimization. Jason was a founding member of Merck’s chemical biology group and a co-lead of Merck’s targeted protein degradation group. Jason contributed to the discovery of five development candidates, three INDs and was a co-inventor in the discovery of the beta-lactamase inhibitor Relebactam. Jason has authored over 30 peer-reviewed journal articles and holds 12 patents spanning a diverse set of therapeutic areas. He holds a bachelor of arts degree in biology and bachelor of science degree in chemistry from the University of Massachusetts in Amherst, Mass. where he was a recognized Howard Hughes Undergraduate Research Fellow, a doctor of philosophy degree in organic chemistry from the University of Arizona in Tucson, Az. and a National Institute of Health Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship at Boston College in Chestnut Hill, Mass.
Kevin	Kreutter	Vice President, Drug Discovery	Empress Therapeutics	https://proventainternational.com/wp-content/uploads/2022/06/Kevin-Kreutter.jpg	Kevin began his Drug Discovery career at 3DP, then Janssen, before moving to the Boston area. Formerly at Nimbus and now at a Flagship NewCo, he’s worked across therapeutic areas and is co-inventor of three clinical candidates, including the gut tissue-restricted pan-JAK inhibitor lorpucitinib. He’s currently VP of Drug Discovery at VL54 Toran + VL55 Empress and his team uses med chem, chemoproteomics, and synthetic biology to help develop novel therapeutics based on co-evolved, human-experienced molecules that play a privileged role in human health.
Stephanos	Loannidis	EVP Drug Discovery	Exo Therapeutics	https://proventainternational.com/wp-content/uploads/2022/09/Stephanos-Ioannidis.jpg	Dr. Loannidis has over 20 years of experience in oncology, neuroscience, and inflammation drug development with a particular focus in early discovery to delivery of IND. Prior to joining Exo, Dr. Ioannidis was Executive Vice President, Head of Discovery at IFM Therapeutics where he led the company’s drug discovery group focused on innate immune system therapeutics. Dr. Ioannidis has also held roles of increasing responsibility at H3 Biomedicine, FORMA Therapeutics, and AstraZeneca R&D. Dr. Ioannidis earned his PhD in Synthetic Organic Chemistry from the Imperial College of Science, Technology and Medicine at University of London and completed his postdoctoral fellow at Harvard University.
Kristen	Marino	Senior Scientist II, Computational Chemistry	Cellarity	https://proventainternational.com/wp-content/uploads/2022/11/Kristen-Marino.jpg
Andrew	McRiner	Vice President, Head of Drug Discovery	Auron Therapeutics	https://proventainternational.com/wp-content/uploads/2022/06/Andrew-McRiner.jpg	Dr. McRiner joined Auron Therapeutics in December 2020 as VP, Head of Drug Discovery. Prior to this, he was Director and Head of MedChem at X-Chem Pharmaceuticals, developing a portfolio of 8 small molecules and 8 degrader programs derived from DEL screening. In total, Dr. McRiner has almost 20 years of experience leading drug discovery programs at pharmaceutical companies such as Novartis, Schering-Plough, and Merck, and biotechs such as Helicon Therapeutics (renamed as DART Neuroscience) and Forum Pharmaceuticals (originally Envivo Pharmaceuticals). He has experience leading projects in multiple therapeutic areas, is co-inventor on over 25 patent applications, and has contributed to the nomination of 12 compounds for clinical development.
Benoit	Moreau	Head of Medicinal Chemistry	Remix Therapeutics	https://proventainternational.com/wp-content/uploads/2022/11/Benoit-Moreau-3.jpg	Benoit Moreau is the head of medicinal chemistry at Remix Therapeutics, a biotech focused on controlling gene and protein expression through modulation of RNA processing. He has over 15 years of experience in drug discovery, building and leading teams in medicinal chemistry at Boehringer Ingelheim, Tarveda and Syros. He contributed to the discovery of several clinical candidates on projects across virology, oncology and rare genetic diseases. He received his PhD in synthetic chemistry from Université de Montréal and completed postdoctoral studies at Harvard University.
Robb	Nicewonger	Senior Director, Medicinal Chemistry	Cellarity	https://proventainternational.com/wp-content/uploads/2022/11/Robb-Nicewonger.jpg
Ed	Olhava	Senior Vice President, Preclinical Development	IFM Therapeutics	https://proventainternational.com/wp-content/uploads/2022/08/Ed-Olhava.jpg	Over his nearly 20 year career in mid and early-stage biotech, Ed Olhava has invented and progressed multiple compounds through discovery and into clinical development. He has focused on discovering first-in-class small molecule modulators of new biological pathways, closely integrating medicinal chemistry, pharmacology, safety and CMC to enter clinical trials with these novel entities. Before joining IFM, Ed was a strategic advisor at Third Rock Ventures, where he developed the strategic and operational plans for the drug discovery groups of two Third Rock seed companies, both of which were successfully funded and launched. Prior to Third Rock, he was a founding scientist at Epizyme, joining the company as the first medicinal chemist. He started the medicinal chemistry group and invented Epizyme’s first clinical compound and the first clinical histone methyltransferase inhibitor, EPZ-5676, leading activities from hit finding to filing the Investigational New Drug application. Before joining Epizyme, Ed began his medicinal chemistry career at Millennium Pharmaceuticals, where he co-invented NINLARO, approved in 2015 for the treatment of multiple myeloma, and MLN-4924. Ed obtained his Ph.D. in synthetic organic chemistry from Harvard University and B.S. in chemistry from Stanford University. He is co-author/inventor on more than 40 papers and patents.
Lewis	Pennington	Senior Director. Head of Platform Chemistry	Kymera Therapeutics	https://proventainternational.com/wp-content/uploads/2022/08/Lewis-Pennington-1.jpg	Lewis D. Pennington is Senior Director and Head of Platform Chemistry at Kymera Therapeutics. His research interests include drug discovery and defining strategies and tactics for multiparameter optimization in small molecule drug design. He previously served a variety of roles as a synthetic and medicinal chemist at Alkermes in Waltham, Massachusetts, Amgen in Thousand Oaks, California, Array BioPharma in Longmont, Colorado, and Eli Lilly & Co. in Indianapolis, Indiana. He earned a B.S. in Chemistry (with Highest Honors in Chemistry) under the guidance of Professor Masato Koreeda at the University of Michigan in Ann Arbor, Michigan and a Ph.D. in Chemistry under the mentorship of Professor Larry Overman at the University of California in Irvine, California.
Nisha	Perez	Senior Director, Head of DMPK	ROME Therapeutics	https://proventainternational.com/wp-content/uploads/2022/08/Heather-Carlson-1.jpg	Nisha Perez is the Senior Director and Head of DMPK at Rome Therapeutics in Cambridge, MA. Formerly, she worked at Blueprint Medicines as Director of DMPK and Clinical Pharmacology and before that, she spent 12 years at Ironwood Pharmaceuticals. She has worked across multiple therapeutic areas including cancer, immuno-oncology, rare diseases, fibrosis, inflammation, women’s health, and GI. She has contributed to multiple program strategies and regulatory filings. She has had the honor of following several candidates into the clinic, through approval and post-marketing requirements. She holds 2 patents, one being an LCMS diagnostic biomarker method.
Jennifer	Petter	Founder and Chief Scientific Officer	Arrakis Therapeutics	https://proventainternational.com/wp-content/uploads/2021/02/Jennifer-Petter.jpeg	Dr. Jennifer Petter is the Founder and Chief Innovation Officer of Arrakis Therapeutics. Previously she was Vice President of Chemistry at Celgene, Vice President of Drug Discovery at Avila Therapeutics, Vice President of Research at Mersana Therapeutics, Director of Small Molecule Drug Discovery at Biogen, Section Head in Oncology Chemistry at Sandoz/Novartis, and Assistant Professor of Chemistry at the University of Pittsburgh. Dr. Petter graduated from Dartmouth College with an AB in chemistry, earned her PhD in organic chemistry at Duke University with Ned Porter, and was a post-doctoral fellow in Ron Breslow’s group at Columbia University. She has ushered multiple compounds into the clinic for the treatment of cancer, cardiovascular disease, autoimmune disorders, and sepsis.
Daniel	J. Price	Executive Director, Head of Computational Chemistry	Nimbus Therapeutics	https://proventainternational.com/wp-content/uploads/2022/06/Daniel-J.-Price.jpg	Dr. Daniel Price is Executive Director and Head of Computational Chemistry at Nimbus Therapeutics. Before joining Nimbus, he a Senior Director in Computational Sciences at GlaxoSmithKline, where he led a small team of computational chemists, chemoinformaticians and data scientists operating across diverse areas of structure- and ligand-based drug design, high-content screening analytics, predictive ADME, predictive synthesis, and chemogenomics. He has led drug discovery programs, contributed to 4 clinical candidates, led the development of GSK’s first-generation R&D “data lake”, and authored/co-authored 25 publications. Dr. Price received his undergraduate degree in chemical engineering from University of Colorado at Boulder followed by his Ph.D. in Molecular Biophysics & Biochemistry from Yale University with Prof. Bill Jorgensen. He completed an NIH postdoctoral fellowship with Prof. Charlie Brooks, III at The Scripps Research Institute prior to joining GSK.
Aimee	Usera	Senior Vice President Drug Discovery	Odyssey Therapeutics	https://proventainternational.com/wp-content/uploads/2022/06/Aimee-Usera-1.jpg	Aimee Usera is a synthetic organic chemist who obtained her PhD from Johns Hopkins University under Professor Gary Posner, and her post doc at MIT working with Professor Sarah O’Connor. Aimee began her career at Novartis Institute for Biomedical Research (NIBR) where she invented new protein chemistry and half-life extension methods, as well as discovered chemical biologic therapeutic clinical candidates. Aimee gained experience across disease areas and modalities, more recently leading the global NIBR Targeted Protein Degradation Initiative. Aimee is currently vice president of chemistry at Odyssey therapeutics where she is focusing on enabling sciences to accelerate the project portfolio.

Dr. Tao Guo, Andreas Schoops, Greg Makara, Onur Atasoylu, Matt Bursavich, Heather Carlson, Richard Heidebrecht, Jason Imbriglio, Kevin Kreutter, Stephanos Loannidis, Kristen Marino, Andrew McRiner, Benoit Moreau, Robb Nicewonger, Ed Olhava, Lewis Pennington, Nisha Perez, Jennifer Petter, Daniel J. Price, Aimee Usera

See the full agenda and facilitator line-up

Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Who Should Attend the Event?

Chief Executive Officers

Executive Vice Presidents

Vice Presidents

Executive Directors

Directors

Global Heads

Responsible For:

Medicinal Chemist

Computational Chemist

Translational

Chemist/Biology

In-Silico/In-vivo/In-vitro Chemist/Biologist

Chemical Biology

Molecular Chemist/Biologist

Hit and Lead Chemist

Small/Large Molecules Chemist

Drug Discovery or Drug Development

See Which Topics Are Discussed at the Strategy Meeting

08:30 – 09:00

Advantages and Limitations in Targeting RNA with Small Molecules

09:00 – 10:00

Roundtable Tracks

Revolutionizing Drug Discovery Through AI/ML Technology To Significantly Reduce The Issues In Early Phase Discovery An Exploration For Fragment-Based Drug Discovery: Discussing How To Effectively Navigate Fragment-Based Drug Discovery Method Innovative Approaches To Early Drug Discovery Through Novel Chemical Modalities Exploring The Ability Of Small Molecules In Modulating The Protein-Protein Interactions To Further Widen The Understanding About The Promising Targets For Drug Discovery The Art Of The Chemical Probe: Addressing The Limitations And Opportunities Of Chemical Probes For Early Drug Discovery Advancing An Integrated Drug Discovery Approach Through Innovations In Drug Discovery Services To Attain A More Efficient And Potent Drug Development

10:30 – 10:50

11:00 – 12:10

Roundtable Tracks

Strategy and Implementation for Innovative and Emerging Modalities Drug Discovery WUXI APPTEC

Hit Identification Technologies and Cracking Undruggable Targets – Which Technology to Choose? WUXI APPTEC

Reasons To Attend the Strategy Meeting

Discussions on the advancements in targeted protein degradation and pushing past its boundaries.

Leveraging Artificial Intelligence and Machine Learning in accelerating the development of new drugs

Discuss approaches to further understand the interactions of undruggable targets and different Protein Degraders such as PROTACs, Molecular Glues, etc

Focusing on advancing interrogative techniques to improve the Drug Delivery System/Discovery: Modified mRNA, Nanoparticle-Mediated siRNA, Antibody-Drug Conjugates, and more

Press play to hear what your colleagues had to say…

Become an official strategy meeting partner

Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Medicinal Chemistry Strategy Meeting East Coast – Boston 2024

Medicinal Chemistry

Strategy Meeting East Coast USA 2022

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge Boston

Fresh Medicinal Chemistry Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our 2022 Facilitators

Dr. Tao Guo

Andreas Schoops

Greg Makara

Onur Atasoylu

Matt Bursavich

Heather Carlson

Richard Heidebrecht

Jason Imbriglio

Kevin Kreutter

Stephanos Loannidis

Kristen Marino

Andrew McRiner

Benoit Moreau

Robb Nicewonger

Ed Olhava

Lewis Pennington

Nisha Perez

Jennifer Petter

Daniel J. Price

Aimee Usera

See the full agenda and facilitator line-up

Who Should Attend the Event?

Chief Executive Officers

Executive Vice Presidents

Vice Presidents

Executive Directors

Directors

Global Heads

Responsible For:

Medicinal Chemist

Computational Chemist

Translational

Chemist/Biology

In-Silico/In-vivo/In-vitro Chemist/Biologist

Chemical Biology

Molecular Chemist/Biologist

Hit and Lead Chemist

Small/Large Molecules Chemist

Drug Discovery or Drug Development

See Which Topics Are Discussed at the Strategy Meeting

REGISTRATION AND WELCOME

OPENING KEYNOTE PRESENTATION

Advantages and Limitations in Targeting RNA with Small Molecules

Roundtable

Roundtable Tracks

REFRESHMENT BREAK

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

Roundtable

Roundtable Tracks

Strategy and Implementation for Innovative and Emerging Modalities Drug Discovery WUXI APPTEC

Hit Identification Technologies and Cracking Undruggable Targets – Which Technology to Choose? WUXI APPTEC

NETWORKING LUNCH

Reasons To Attend the Strategy Meeting

Our 2022 Leader Sponsor

Our 2022 Co-Hosts

Press play to hear what your colleagues had to say…

Become an official strategy meeting partner

Here To Help

Le Meridien Cambridge Boston